AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29056072 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (Control)
Number of subjects: 206
Study 29056072 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (Intervention)
Number of subjects: 206
Study 27809796 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week web-based stress management intervention (STREAM) with weekly written feedback by a psychologist
Number of subjects: 120
Study 27809796 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 120
Study 25350546 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple text message reminders
Number of subjects: 1140
Study 25350546 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional message with adherence statement
Number of subjects: 1140
Study 25350546 — intervention group
Group type: COMPARATOR
Intervention: Control group (no text message reminders)
Number of subjects: 1140
Study 22199194 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory frequency discrimination task (AFD group)
Number of subjects: 86
Study 22199194 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory phonetic discrimination task (PD group)
Number of subjects: 86
Study 22199194 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual frequency discrimination task (VFD group)
Number of subjects: 86
Study 22199194 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control (NI group)
Number of subjects: 86
Study 20136803 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum interferential current (IFC) therapy
Number of subjects: 44
Study 20136803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 18853934 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem extended-release 12.5 mg
Number of subjects: 752
Study 16815535 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported smokers
Number of subjects: 328
Study 16815535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotinine-derived smokers
Number of subjects: 328
Study 12826548 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 0.375%
Number of subjects: 30
Study 12826548 — intervention group
Group type: COMPARATOR
Intervention: Postoperative local anesthetics and supplemental analgesics
Number of subjects: 30
Study 12826548 — intervention group
Group type: COMPARATOR
Intervention: Dynamic pain scores
Number of subjects: 30
Study 12826548 — intervention group
Group type: COMPARATOR
Intervention: Side effects
Number of subjects: 30
Study 10893016 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 100 microg once daily
Number of subjects: 57
Study 10893016 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 200 microg once daily
Number of subjects: 57
Study 10893016 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 100 microg twice daily
Number of subjects: 57
Study 10893016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 10893016 — intervention group
Group type: EXPERIMENTAL
Intervention: All budesonide groups
Number of subjects: 57
Study 8835835 — intervention group
Group type: EXPERIMENTAL
Intervention: VSF-ECG method (Voltage Sum of Filtered ECG)
Number of subjects: 0
Study 1442757 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 to 40 mg/d)
Number of subjects: 33
Study 1442757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 3910296 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 280 mg mefloquine, 800 mg sulfadoxine and 40 mg pyrimethamine
Number of subjects: 75
Study 3910296 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 420 mg mefloquine, 1200 mg sulfadoxine and 60 mg pyrimethamine
Number of subjects: 75
Study 3910296 — intervention group
Group type: COMPARATOR
Intervention: Combination of 1500 mg sulfadoxine and 75 mg pyrimethamine
Number of subjects: 75
Study 30626217 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip training (IHT)
Number of subjects: 33
Study 30626217 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 30886093 — intervention group
Group type: EXPERIMENTAL
Intervention: Seniors in the United States
Number of subjects: 0
Study 30886093 — intervention group
Group type: EXPERIMENTAL
Intervention: Seniors in elite institutions in the United States
Number of subjects: 0
Study 30886093 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 0
Study 28492197 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC) restorations
Number of subjects: 86
Study 28492197 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin (CR) restorations
Number of subjects: 86
Study 26478951 — intervention group
Group type: EXPERIMENTAL
Intervention: Busy Bodies/Better Bites Obesity Prevention Arm
Number of subjects: 60
Study 26478951 — intervention group
Group type: COMPARATOR
Intervention: Healthy Tots/Safe Spots safety/injury prevention Contact Control Arm
Number of subjects: 60
Study 23493965 — intervention group
Group type: EXPERIMENTAL
Intervention: Talbinah consumption
Number of subjects: 30
Study 20853262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular Response Analyzer (ORA)
Number of subjects: 154
Study 20853262 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometry (GAT)
Number of subjects: 154
Study 20853262 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal hysteresis (CH)
Number of subjects: 154
Study 20853262 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal resistance factor (CRF)
Number of subjects: 154
Study 20853262 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical medications
Number of subjects: 154
Study 20853262 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin analogues
Number of subjects: 154
Study 18076041 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of triglycerides (>/=160 mg/dl)
Number of subjects: 2299
Study 18076041 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quintile of HDL (<30 mg/dl)
Number of subjects: 2299
Study 18076041 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol, LDL, and apo A
Number of subjects: 2299
Study 18076041 — intervention group
Group type: EXPERIMENTAL
Intervention: Low and high levels of total cholesterol, LDL, apo A, and apo B
Number of subjects: 2299
Study 16549410 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley's manoeuvre
Number of subjects: 66
Study 16549410 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 66
Study 15309442 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bran breads (10.2 mg ferulic acid per day)
Number of subjects: 18
Study 15309442 — intervention group
Group type: COMPARATOR
Intervention: Control breads (inert wheat bran)
Number of subjects: 18
Study 15309442 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bran intervention
Number of subjects: 18
Study 11057849 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 6595
Study 9223886 — intervention group
Group type: EXPERIMENTAL
Intervention: Normovolemic hemodilution with Dextran 40 (Group II)
Number of subjects: 156
Study 9223886 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin and lactated Ringer solution (Group III)
Number of subjects: 156
Study 9223886 — intervention group
Group type: COMPARATOR
Intervention: Without hemodilution (Group I)
Number of subjects: 156
Study 8267190 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine (300 micrograms)
Number of subjects: 26
Study 8267190 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine (700 micrograms)
Number of subjects: 26
Study 8267190 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label continuous epidural infusion of clonidine (10-50 micrograms/h)
Number of subjects: 26
Study 8267190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 4005106 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 9
Study 4005106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31097085 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line afatinib
Number of subjects: 553
Study 31097085 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 553
Study 31097085 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Number of subjects: 553
Study 28951026 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping partnership intervention (1 home visit, weekly telephone calls for month 1, biweekly calls for months 2 and 3)
Number of subjects: 66
Study 28951026 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 66
Study 27390074 — intervention group
Group type: EXPERIMENTAL
Intervention: Water dispensers with promotional activities and cups
Number of subjects: 595
Study 27390074 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottleless water coolers with promotional activities and cups
Number of subjects: 595
Study 27390074 — intervention group
Group type: COMPARATOR
Intervention: Traditional drinking fountains with no cups or promotion
Number of subjects: 595
Study 25322696 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital photographs of plain film CXRs
Number of subjects: 150
Study 25322696 — intervention group
Group type: COMPARATOR
Intervention: Plain film CXRs viewed on a light box
Number of subjects: 150
Study 25322696 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of both modalities
Number of subjects: 150
Study 25322696 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for lung carcinoma and pneumonia images
Number of subjects: 150
Study 25322696 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for pneumothorax, tuberculosis, interstitial disease, and normal images
Number of subjects: 150
Study 22884414 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (200mg, orally at 23:00 h and again at 4:00 h)
Number of subjects: 11
Study 22884414 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 11
Study 19655179 — intervention group
Group type: EXPERIMENTAL
Intervention: DIAGNOdent (LF)
Number of subjects: 166
Study 19655179 — intervention group
Group type: EXPERIMENTAL
Intervention: DIAGNOdent (LFpen)
Number of subjects: 166
Study 19655179 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealants (two clear and two opaque)
Number of subjects: 166
Study 17074300 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (CBT) in RCT (N=30)
Number of subjects: 414
Study 17074300 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behaviour therapy (CBT) in routine practice (N=384)
Number of subjects: 414
Study 16236225 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored internet-delivered newsletters
Number of subjects: 31
Study 16236225 — intervention group
Group type: COMPARATOR
Intervention: Standard internet-delivered newsletters
Number of subjects: 31
Study 12099542 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide 2% three times daily for 12 weeks
Number of subjects: 215
Study 12099542 — intervention group
Group type: COMPARATOR
Intervention: Acetazolamide 250-mg q.i.d. for 12 weeks
Number of subjects: 215
Study 12099542 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 215
Study 12099542 — intervention group
Group type: COMPARATOR
Intervention: Acetazolamide
Number of subjects: 215
Study 10847958 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L of gas flow through the perfusate before bypass, starting FIO2 of 0.80
Number of subjects: 39
Study 10847958 — intervention group
Group type: EXPERIMENTAL
Intervention: No gas flow through the perfusate prior to bypass, starting FIO2 of 0.21
Number of subjects: 39
Study 10847958 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L of gas flowing through the perfusate, starting FIO2 of 0.21
Number of subjects: 39
Study 10847958 — intervention group
Group type: EXPERIMENTAL
Intervention: High FIO2 settings
Number of subjects: 39
Study 8678268 — intervention group
Group type: EXPERIMENTAL
Intervention: glucose solution + lipid emulsion
Number of subjects: 20
Study 8678268 — intervention group
Group type: COMPARATOR
Intervention: fructose solution + lipid emulsion
Number of subjects: 20
Study 1964153 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (1000 mg/m2 cyclophosphamide, 50 mg/m2 doxorubicin, 1.4 mg/m2 vincristine)
Number of subjects: 170
Study 1964153 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy using three different drug-combinations (A: 1500 mg/m2 cyclophosphamide, 100 mg/m2 lomustine, 15 mg/m2 methotrexate; B: 1000 mg/m2 cyclophosphamide, 40 mg/m2 doxorubicin, 1 mg/m2 vincristine; C: 5 x 1.6 g/m2 ifosfamide plus mesna, 5 x 120 mg/m2 etopside)
Number of subjects: 170
Study 1964153 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery followed by chemotherapy and radiotherapy
Number of subjects: 170
Study 418984 — intervention group
Group type: EXPERIMENTAL
Intervention: Monistat Cream for 7 days
Number of subjects: 0
Study 418984 — intervention group
Group type: COMPARATOR
Intervention: Monistat Cream for 14 days
Number of subjects: 0
Study 30520013 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 infusions of rituximab (375 mg/m2) in combination with CHOEP chemotherapy
Number of subjects: 77
Study 30520013 — intervention group
Group type: COMPARATOR
Intervention: 6 infusions of rituximab (375 mg/m2) in combination with CHOEP chemotherapy (control group)
Number of subjects: 77
Study 29490769 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride and fluticasone propionate (AZE/FP)
Number of subjects: 404
Study 29490769 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 404
Study 27003488 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 70
Study 27003488 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study 23867044 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid stenting (n = 81)
Number of subjects: 139
Study 23867044 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA) (n = 58)
Number of subjects: 139
Study 22209640 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication (individualized dose of psychostimulants such as methylphenidate or dextroamphetamine/amphetamine combination)
Number of subjects: 18
Study 22209640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 22209640 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication
Number of subjects: 18
Study 19875400 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital at home (HaH) care
Number of subjects: 80
Study 19875400 — intervention group
Group type: COMPARATOR
Intervention: Inpatient hospital care (IHC)
Number of subjects: 80
Study 17177040 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational DVD (n = 22)
Number of subjects: 49
Study 17177040 — intervention group
Group type: COMPARATOR
Intervention: Placebo DVD (n = 27)
Number of subjects: 49
Study 15314858 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin administration in doses exceeding routine ones
Number of subjects: 161
Study 15314858 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cryoprecipitate
Number of subjects: 161
Study 11889659 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored self-care treatment program
Number of subjects: 0
Study 11889659 — intervention group
Group type: COMPARATOR
Intervention: Usual TMD treatment
Number of subjects: 0
Study 9797623 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (n=62)
Number of subjects: 87
Study 9797623 — intervention group
Group type: COMPARATOR
Intervention: Non-morphine treatment (n=33)
Number of subjects: 87
Study 8592594 — intervention group
Group type: EXPERIMENTAL
Intervention: CU (cuprammonium) dialyser
Number of subjects: 8
Study 8592594 — intervention group
Group type: EXPERIMENTAL
Intervention: CTA (cellulose triacetate) dialyser
Number of subjects: 8
Study 8592594 — intervention group
Group type: EXPERIMENTAL
Intervention: All membranes (CTA, CU, PS)
Number of subjects: 8
Study 8592594 — intervention group
Group type: EXPERIMENTAL
Intervention: CTA, CU, PS (all membranes)
Number of subjects: 8
Study 2378776 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1.34 mg/kg of LTM for ED50, 2.56 mg/kg of LTM for ED95)
Number of subjects: 56
Study 2378776 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 56
Study 334609 — intervention group
Group type: EXPERIMENTAL
Intervention: Butacote, 200 mg b.d. for four weeks
Number of subjects: 48
Study 334609 — intervention group
Group type: COMPARATOR
Intervention: Naproxen, 250 mg b.d. for four weeks
Number of subjects: 48
Study 31121476 — intervention group
Group type: EXPERIMENTAL
Intervention: Westmead Program
Number of subjects: 91
Study 31121476 — intervention group
Group type: COMPARATOR
Intervention: Lidcombe Program
Number of subjects: 91
Study 31121476 — intervention group
Group type: COMPARATOR
Intervention: Control (Lidcombe Program)
Number of subjects: 91
Study 28082464 — intervention group
Group type: EXPERIMENTAL
Intervention: OFF-to-ON conversion (emergent)
Number of subjects: 4718
Study 28082464 — intervention group
Group type: EXPERIMENTAL
Intervention: OFF-to-ON conversion (elective)
Number of subjects: 4718
Study 28082464 — intervention group
Group type: COMPARATOR
Intervention: Non-converted off-pump patients
Number of subjects: 4718
Study 25892679 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early mobilisation
Number of subjects: 2104
Study 25892679 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2104
Study 23894322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (individual lifestyle counselling, family session, cooking classes, supervised physical activity programme)
Number of subjects: 536
Study 23894322 — intervention group
Group type: COMPARATOR
Intervention: Control group (generic lifestyle advice)
Number of subjects: 536
Study 23894322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 536
Study 23894322 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 536
Study 20717066 — intervention group
Group type: EXPERIMENTAL
Intervention: External pancreatic duct stent (n=23)
Number of subjects: 45
Study 20717066 — intervention group
Group type: COMPARATOR
Intervention: No external pancreatic duct stent (n=22)
Number of subjects: 45
Study 19185773 — intervention group
Group type: EXPERIMENTAL
Intervention: GoChi (120 mL/d)
Number of subjects: 50
Study 19185773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 16888542 — intervention group
Group type: COMPARATOR
Intervention: Classic microlumbar discectomy (Group A)
Number of subjects: 20
Study 16888542 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservation of the ligamentum flavum during microlumbar discectomy (Group B)
Number of subjects: 20
Study 14740178 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression-Estimated Input Function (REIF) method
Number of subjects: 44
Study 14740178 — intervention group
Group type: COMPARATOR
Intervention: Real input functions
Number of subjects: 44
Study 12621592 — intervention group
Group type: EXPERIMENTAL
Intervention: Public sector primary care patients
Number of subjects: 115
Study 12621592 — intervention group
Group type: COMPARATOR
Intervention: Middle-income clinics patients
Number of subjects: 115
Study 10197889 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive megavitamin and dietary treatment
Number of subjects: 19
Study 10197889 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving 25 mg vitamin C and allergenic substances
Number of subjects: 19
Study 8527549 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin (600 mg/d) in combination with ethambutol, streptomycin, and clarithromycin (500 mg b.i.d.)
Number of subjects: 26
Study 8527549 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin (600 mg/d) in combination with ethambutol, streptomycin, and azithromycin (600 mg/d)
Number of subjects: 26
Study 8527549 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin (600 mg/d)
Number of subjects: 26
Study 2273082 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa (250 mg tid) for 14 days
Number of subjects: 16
Study 2273082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7378251 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Phyllocontin Continus tablets and salbutamol)
Number of subjects: 20
Study 7378251 — intervention group
Group type: COMPARATOR
Intervention: Phyllocontin Continus tablets
Number of subjects: 20
Study 7378251 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 20
Study 30677187 — intervention group
Group type: COMPARATOR
Intervention: Usual basal insulin dose
Number of subjects: 10
Study 30677187 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced (75%) basal insulin dose
Number of subjects: 10
Study 30677187 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sensor performance
Number of subjects: 10
Study 30677187 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor performance during hypoglycaemia
Number of subjects: 10
Study 30677187 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor performance during euglycaemia
Number of subjects: 10
Study 30677187 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor performance during hyperglycaemia
Number of subjects: 10
Study 30677187 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall glucose levels during exercise
Number of subjects: 10
Study 28515020 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (2-2.7g/d)
Number of subjects: 154
Study 28515020 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA supplementation (1-2.7g/d)
Number of subjects: 154
Study 28515020 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (0g of EPA+DHA)
Number of subjects: 154
Study 25823535 — intervention group
Group type: EXPERIMENTAL
Intervention: CAIX score ≥ 200
Number of subjects: 813
Study 25823535 — intervention group
Group type: COMPARATOR
Intervention: CAIX score ≤ 100
Number of subjects: 813
Study 25823535 — intervention group
Group type: EXPERIMENTAL
Intervention: CAIX > 85%
Number of subjects: 813
Study 23449126 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical enzymatically generated hydrogen peroxide (using glucose oxidase and glucose)
Number of subjects: 0
Study 21538146 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 135